Alkermes to Present New Data on Alixorexton for Narcolepsy Type 1 at AAN 2026
Alkermes plc has announced plans to present new data from its Vibrance-1 phase 2 study on alixorexton, a novel orexin 2 receptor agonist, at the American Academy of Neurology (AAN) 2026 Annual Meeting. The study involved 92 patients with narcolepsy type 1 (NT1) and demonstrated significant improvements in wakefulness, cognition, and fatigue compared to placebo. The new data, which will be presented, show sustained improvements in excessive daytime sleepiness and cataplexy through a seven-week open-label extension. Alixorexton was generally well tolerated, with no serious adverse events reported. The study's findings support the ongoing phase 3 Brilliance NT1 study, aiming to further evaluate alixorexton's efficacy and safety. 
